Merck Oncology Clinical Trials for Head and Neck Cancer

Merck is passionate about improving health. We are committed to accelerating every step in the journey in our quest to bring treatment options to people with cancer. These clinical trials for head and neck cancer are investigating different study medications alone, or in combination with other study medications, or standard of care therapy, to see if they can help prevent, find, or treat cancer.

Participating in a clinical trial is an important decision. Anyone participating in a trial should know as much as possible about what is being studied, what risks are involved and what potential benefits may be gained before deciding to enroll. If you are interested in participating in a clinical trial, please talk to your doctor first.

You can also call our clinical trial information center at 1-888-577-8839 to learn more.

Active Clinical Trials

Trial Description Trial Number Condition Phase Status
Study of Pembrolizumab or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma
412 Head and Neck Neoplasms Phase 3 Active, not recruiting
Study of Pembrolizumab in Adults With Recurrent/Metastatic Cutaneous Squamous Cell Carcinoma or Locally Advanced Unresectable cSCC
629 Squamous Cell Carcinoma Phase 2 Recruiting
Pembrolizumab Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma
630 Carcinoma, Squamous Cell Phase 3 Recruiting
Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma
689 Head and Neck Neoplasms Phase 3 Recruiting
Pembrolizumab Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer
040 Head and Neck Squamous Cell Cancer Phase 3 Active, not recruiting
A Study of Pembrolizumab for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck
048
  • Recurrent Head and Neck Cancer
  • Metastatic Head and Neck Cancer
Phase 3 Active, not recruiting
Study of MK-3475 in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy
055 Head and Neck Squamous Cell Carcinoma Phase 2 Active, not recruiting
Study of Pembrolizumab in Platinum Pre-treated Recurrent/Metastatic Nasopharyngeal Cancer
122 Nasopharyngeal Neoplasms Phase 3 Active, not recruiting

Clinical Trials: Important Information to Consider

There is a lot to consider when deciding whether to participate in a clinical study. Any clinical study includes risks, which the study doctor will review with you. Make sure you understand the risks before participating.